MT4C Antibody

What is the MT4 monoclonal antibody and what is its primary target?

MT4 is a monoclonal antibody specifically targeting the CD4 protein. It has been validated through various methods, including reactivity with CD4-DNA transfected COS cells, CD4+ cell lines, and CD4+ lymphocytes. The antibody has been proven to inhibit the binding of standard CD4 monoclonal antibodies to CD4 proteins on CD4+ cells, confirming its specificity . This antibody has applications in flow cytometry when conjugated with fluorescein isothiocyanate (FITC) and has been used in HIV research contexts for monitoring CD4+ lymphocyte counts.

How does the MT4/3 antibody differ from the standard MT4 antibody?

While both target CD4 molecules, MT4/3 demonstrates distinct functional properties compared to MT4. Studies have shown that MT4/3 can inhibit anti-CD3 induced T cell proliferation at concentrations of 10 and 40 μg/ml, whereas the standard MT4 antibody does not demonstrate this inhibitory effect at the same concentrations . MT4/3 specifically affects CD4 molecules on monocytes, leading to decreased cytokine production (IL-2, IFN-γ, TNF-α, and IL-17A) by CD3+ T cells and reduced expression of costimulatory molecules on monocytes .

What is MT4-MMP antibody and how is it different from MT4 antibodies targeting CD4?

MT4-MMP antibody (also referred to as anti-MMP17) targets Matrix metalloproteinase-17, which is entirely different from the CD4 glycoprotein. MMP17 is an endopeptidase that degrades extracellular matrix components, particularly fibrin, and may be involved in activating membrane-bound precursors of growth factors or inflammatory mediators like tumor necrosis factor-alpha . Unlike the CD4-targeting MT4 antibody, MT4-MMP antibody recognizes a protein with a molecular weight of approximately 67-75 kDa and is typically used in applications like Western blot, immunohistochemistry, and immunocytochemistry.

How can MT4 antibody be used for CD4+ lymphocyte quantification in research settings?

For CD4+ lymphocyte quantification, the MT4 antibody can be conjugated with fluorescein isothiocyanate (FITC) and used in flow cytometry. Research has demonstrated that FITC-labeled MT4 antibody produces comparable results to commercial reagents for both percentage and absolute CD4+ lymphocyte counts. In a study involving 30 HIV-infected and 30 healthy individuals, the correlation coefficient for regression analysis was 0.995 for percentages and 0.996 for absolute CD4+ lymphocyte counts when comparing MT4-based reagents with commercial kits . This validates its use as a reliable alternative in research contexts where commercial reagents may be unavailable or cost-prohibitive.

What experimental design would be appropriate to study the immunoregulatory function of CD4 on monocytes using MT4/3 antibody?

Based on published methodologies, an appropriate experimental design would include:

• Cell Isolation and Preparation:

  • Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors

  • Separate monocyte and T cell populations using magnetic selection or flow cytometry sorting

• Experimental Conditions:

  • Treatment groups: MT4/3 antibody (10μg/ml and 40μg/ml), isotype-matched control antibody, no antibody control

  • Pre-pulse monocytes with MT4/3 for 15-30 minutes in some experiments to isolate monocyte-specific effects

• Functional Assays:

  • T cell proliferation: CFSE-labeled T cells co-cultured with monocytes and anti-CD3 stimulation

  • Cytokine production: Measure IL-2, IFN-γ, TNF-α, IL-17A, IL-10, and IL-6 levels using ELISA or flow cytometry

  • Costimulatory molecule expression: Flow cytometric analysis of CD14+ monocytes

  • Monocyte migration: Transwell migration assay

  • Differentiation studies: Culture treated monocytes in differentiation conditions and assess macrophage markers

• Data Analysis:

  • Normalize data to medium control or isotype control

  • Use appropriate statistical methods (unpaired t-test for comparing conditions)

What methodological considerations are important when using MT4-MMP antibody in Western blotting?

When using MT4-MMP antibody for Western blotting, several methodological aspects require careful attention:

How can MT4/3 antibody be utilized to investigate the differential roles of CD4 on T cells versus monocytes?

To investigate the differential roles of CD4 on T cells versus monocytes using MT4/3 antibody, researchers can implement a multi-component experimental design:

• Cell Type Isolation and Depletion Studies:

  • Compare the effect of MT4/3 on whole PBMCs versus monocyte-depleted PBMCs

  • Pre-pulse isolated monocytes with MT4/3 before reconstituting with T cells

• Domain-Specific Binding Analysis:

  • Use competitive binding assays with domain-specific anti-CD4 antibodies to determine if MT4/3 recognizes different epitopes on monocyte CD4 versus T cell CD4

• Molecular Weight Comparison:

  • Perform Western blotting on purified CD4 from monocytes (identified as 55 kDa) versus T cells to confirm structural differences

• Downstream Signaling Analysis:

  • Compare signaling pathways activated by MT4/3 in monocytes versus T cells using phosphoprotein analysis

  • Investigate how these different signaling events lead to distinct functional outcomes

• Functional Segregation:

  • Design experiments where either monocyte CD4 or T cell CD4 is selectively blocked by pre-treatment strategies

  • Measure outcomes like T cell activation, cytokine production, and co-stimulatory molecule expression

What are the potential applications of MT4 antibody in HIV research beyond CD4+ lymphocyte counting?

MT4 antibody has several advanced applications in HIV research beyond basic CD4+ lymphocyte counting:

• Viral Entry Studies:

  • Block CD4-dependent HIV entry using different concentrations of MT4 to study the dynamics of viral attachment

  • Compare with other anti-CD4 antibodies to map critical epitopes involved in HIV binding

• Immunomodulatory Approaches:

  • Investigate whether MT4 antibody-mediated CD4 ligation could be used to modulate immune responses in HIV patients

  • Study how CD4 ligation affects HIV reservoir cells without activating latent virus

• Combination Therapy Investigations:

  • Study synergistic effects of MT4 with antiretroviral drugs

  • Evaluate whether CD4 blockade combined with conventional therapy affects viral load dynamics

• Patient Stratification:

  • Develop more nuanced measurements of CD4+ cell functionality beyond simple counting

  • Correlate MT4 binding patterns with disease progression or treatment response

• Mechanism of CD4 Down-regulation:

  • Investigate how HIV-induced CD4 down-regulation relates to epitopes recognized by MT4

  • Use MT4 as a tool to follow CD4 trafficking in infected cells

How can researchers use MT4-MMP antibody to investigate the role of this protease in tumor progression?

To investigate MT4-MMP's role in tumor progression, researchers can implement the following methodological approach:

• Expression Analysis in Clinical Samples:

  • Use MT4-MMP antibodies (like EP1270Y) for immunohistochemistry on tumor sections

  • Compare expression levels between normal tissue, primary tumors, and metastatic sites

• Functional Studies in Cell Models:

  • Detect MT4-MMP in cancer cell lines using Western blot and immunocytochemistry

  • Correlate expression with invasive capacity using invasion assays

• Mechanism Investigation:

  • Examine MT4-MMP's role in activating pro-TNF-alpha by studying the cleavage at the '74-Ala-|-Gln-75' site

  • Investigate interaction with extracellular matrix components, particularly fibrin

• In vivo Models:

  • Use antibodies to detect MT4-MMP in xenograft or syngeneic tumor models

  • Correlate expression with metastatic potential and tumor microenvironment characteristics

• Therapeutic Targeting Assessment:

  • Use MT4-MMP antibodies to evaluate the efficacy of protease inhibitors

  • Develop blocking antibodies based on the epitope recognition of existing antibodies like EP1270Y

What are the common technical challenges when using MT4 antibody in flow cytometry, and how can they be addressed?

When using MT4 antibody in flow cytometry, researchers may encounter several technical challenges:

• Background Fluorescence Issues:

  • Problem: High background signal reducing signal-to-noise ratio

  • Solution: Optimize antibody concentration through titration experiments; use appropriate blocking reagents (human serum for Fc blocking); include fluorescence-minus-one (FMO) controls

• Cross-Reactivity Concerns:

  • Problem: Potential non-specific binding to other surface proteins

  • Solution: Validate specificity using CD4-negative cell populations; use competitive binding assays with well-characterized anti-CD4 antibodies

• Compensation Challenges:

  • Problem: Spillover between FITC-conjugated MT4 and other fluorochromes

  • Solution: Prepare proper single-color controls; optimize compensation matrix; consider alternative fluorochromes if spillover cannot be adequately compensated

• Sample Preparation Variability:

  • Problem: Inconsistent results between samples

  • Solution: Standardize sample processing time and temperature; process all comparative samples simultaneously; use stabilizing fixatives

• Antibody Conjugation Efficiency:

  • Problem: Batch-to-batch variation in FITC conjugation

  • Solution: Validate each new lot against a reference standard; optimize FITC:protein ratio during conjugation

What factors should researchers consider when comparing results obtained with MT4/3 antibody to other anti-CD4 antibodies?

When comparing results obtained with MT4/3 antibody to other anti-CD4 antibodies, researchers should consider:

• Epitope Specificity:

  • Different anti-CD4 antibodies may bind to distinct domains of CD4 molecule

  • MT4/3 may recognize epitopes that are differently expressed or structured on monocytes versus T cells

  • Compare with antibodies targeting known CD4 domains to map the binding site of MT4/3

• Functional Readouts:

  • MT4/3 shows inhibitory effects on T cell proliferation and cytokine production

  • Other anti-CD4 antibodies may be neutralizing, activating, or have no functional effect

  • Compare same functional parameters under identical experimental conditions

• Cell Type Specificity:

  • MT4/3 effects are most prominent on monocyte CD4

  • Other antibodies may predominantly affect T cell CD4

  • Test on purified cell populations to disambiguate effects

• Concentration-Response Relationships:

  • MT4/3 shows inhibitory effects at 10 and 40 μg/ml

  • Test comparative antibodies across multiple concentrations to establish full dose-response curves

• Isotype Controls:

  • Ensure isotype-matched controls are used for each antibody being compared

  • Account for potential Fc-mediated effects independent of CD4 binding

What analytical controls should be included when using MT4-MMP antibody in immunohistochemistry studies?

When using MT4-MMP antibody in immunohistochemistry, the following analytical controls should be included:

• Positive Tissue Controls:

  • Include tissues known to express MT4-MMP (small intestine has been validated)

  • Use multiple positive controls representing different expression levels

• Negative Controls:

  • Isotype control: Replace primary antibody with same concentration of isotype-matched immunoglobulin

  • Antibody omission: Process sections without primary antibody

  • Absorption control: Pre-incubate antibody with immunizing peptide before application

• Specificity Controls:

  • When available, include tissues from MT4-MMP knockout models

  • Use siRNA knockdown tissues or validate with orthogonal methods (ISH)

• Technical Controls:

  • Titration series: Include sections stained with different antibody dilutions (1:50 to 1:200 is recommended)

  • Process controls: Include sections processed on different days to assess reproducibility

• Comparative Controls:

  • Process serial sections with alternative validated anti-MT4-MMP antibodies

  • Compare staining patterns to establish consistency across antibodies

How should researchers interpret contradictory findings between MT4 and MT4/3 antibodies in CD4 functional studies?

When encountering contradictory findings between MT4 and MT4/3 antibodies in CD4 functional studies, researchers should consider the following interpretative framework:

• Epitope Differences:

  • MT4 and MT4/3 likely recognize different epitopes on the CD4 molecule

  • These epitopes may be differentially involved in functional activities of CD4

• Cell-Type Specific Effects:

  • Research shows MT4/3 inhibits T cell proliferation while MT4 does not

  • This suggests MT4/3 recognizes a functionally important epitope on monocyte CD4 that MT4 does not

• Signaling Pathway Analysis:

  • Investigate whether the antibodies activate different downstream signaling pathways

  • Map phosphorylation events following ligation with either antibody

• Structural Implications:

  • Consider that the 55 kDa CD4 on monocytes may have structural differences from T cell CD4

  • These differences might explain differential recognition and functional outcomes

• Experimental Validation Approach:

  • Perform competitive binding assays to determine if the antibodies recognize overlapping epitopes

  • Use domain-specific mutants of CD4 to map precise binding regions

  • Conduct cross-blocking experiments to establish relationship between binding sites

What are the key considerations when analyzing the molecular weight differences of CD4 detected by MT4/3 on monocytes versus T cells?

When analyzing the molecular weight differences of CD4 detected by MT4/3 on monocytes versus T cells, researchers should consider:

Analytical Framework:

• Sample Preparation Consistency:

  • Ensure identical lysis conditions for both cell types

  • Use the same protein quantification method for loading controls

  • Account for differences in membrane protein extraction efficiency

• Western Blot Technical Considerations:

  • Use gradient gels to improve resolution in the 50-60 kDa range

  • Include molecular weight markers that bracket the expected sizes

  • Apply consistent transfer conditions optimized for glycoproteins

• Post-translational Modification Analysis:

  • The observed 55 kDa for monocyte CD4 versus typical 58-60 kDa for T cell CD4 suggests different glycosylation patterns

  • Consider enzymatic deglycosylation experiments (PNGase F, O-glycosidase)

  • Analyze potential differences in other modifications (phosphorylation, ubiquitination)

• Isoform Consideration:

  • Investigate whether monocytes express a specific splice variant of CD4

  • Perform RT-PCR to detect potential alternative transcripts

• Functional Correlation:

  • Correlate molecular weight differences with functional outcomes

  • Consider how structural differences might explain the immunoregulatory role of monocyte CD4

How can researchers integrate findings from MT4 antibody studies with broader understanding of CD4 biology in immune regulation?

To integrate findings from MT4 antibody studies with broader CD4 biology:

• Multifaceted CD4 Functions:

  • Traditional view: CD4 primarily as T cell co-receptor for MHC II recognition

  • Expanded perspective: CD4 as an immunoregulatory molecule on monocytes

  • Integration point: Map how these functions complement each other in immune responses

• Comparative Analysis Framework:

  Aspect	CD4 on T Cells	CD4 on Monocytes (MT4/3 Studies)
  Molecular Weight	58-60 kDa	55 kDa
  Primary Function	MHC II co-receptor	Immunoregulation
  Response to Ligation	T cell activation	Inhibition of T cell responses
  Downstream Effects	IL-2, IFN-γ production	Decreased IL-2, IFN-γ, TNF-α, IL-17A
  Cellular Outcomes	T cell proliferation	Reduced monocyte migration

• Translational Perspectives:

  • MT4/3 findings suggest CD4-targeting approaches might modulate both T cell and monocyte functions

  • This dual targeting could be exploited in conditions where both adaptive and innate immunity need regulation

  • Development of epitope-specific antibodies could selectively target CD4 functions on specific cell types

• Evolutionary Considerations:

  • The differential structure and function of CD4 on monocytes versus T cells suggests evolutionary adaptation

  • This may reflect the need for balanced regulation between innate and adaptive immunity

• Future Research Directions:

  • Map signaling pathways downstream of CD4 in both cell types

  • Investigate tissue-specific differences in CD4 expression and function

  • Explore potential therapeutic applications of MT4/3-like antibodies in autoimmunity or transplantation

What novel research applications might emerge from understanding the differential effects of MT4 versus MT4/3 antibodies?

Understanding the differential effects of MT4 versus MT4/3 antibodies could lead to several novel research applications:

• Selective Immunomodulation:

  • Development of epitope-specific antibodies that selectively target either T cell or monocyte CD4 functions

  • Creation of bifunctional antibodies that engage CD4 and another target to achieve cell-type specific effects

• Diagnostic Applications:

  • Using differential binding patterns to identify altered CD4 expression or structure in disease states

  • Development of assays to quantify the ratio of different CD4 forms as biomarkers

• Therapeutic Targeting:

  • Design of antibodies that selectively inhibit monocyte functions without affecting T cell immunity

  • Creation of small molecule compounds that mimic MT4/3 binding to achieve similar immunoregulatory effects

• Structural Biology:

  • Using antibody binding patterns to inform structural studies of CD4 in different cellular contexts

  • Development of structure-based drug design targeting specific CD4 conformations

• Systems Immunology:

  • Integration of CD4 signaling data from both cell types into comprehensive models of immune regulation

  • Prediction of network effects following selective CD4 targeting

How might researchers apply knowledge from MT4 antibody studies to develop more precise immunotherapeutic approaches?

Knowledge from MT4 antibody studies could inform more precise immunotherapeutic approaches through:

• Epitope-Specific Immunomodulation:

  • Develop antibodies targeting the specific CD4 epitope recognized by MT4/3 for selective immunosuppression

  • Engineer antibody variants with modified Fc regions to enhance or reduce effector functions

• Cell-Type Selective Targeting:

  • Create therapeutic antibodies that preferentially bind monocyte CD4 versus T cell CD4 based on structural differences

  • Develop bispecific antibodies that recognize both CD4 and monocyte-specific markers

• Context-Dependent Activation:

  • Design antibodies that are activated only in specific inflammatory microenvironments

  • Develop conditionally active antibodies that change conformation based on environmental cues

• Combination Approaches:

  • Integrate MT4/3-like CD4 targeting with conventional immunosuppressants at lower doses

  • Combine monocyte CD4 targeting with T cell checkpoint inhibition for balanced immunomodulation

• Personalized Therapy Selection:

  • Develop diagnostic tools based on CD4 expression patterns to predict response to immunomodulatory therapies

  • Match patients to specific anti-CD4 approaches based on their immune profile

What methodological advances would enable better characterization of the MT4-MMP protein targeted by MT4-MMP antibodies?

Several methodological advances would enhance characterization of MT4-MMP:

• Advanced Imaging Techniques:

  • Super-resolution microscopy to visualize MT4-MMP localization in membrane microdomains

  • Live-cell imaging with fluorescently tagged antibodies to track MT4-MMP trafficking and activity

• Proteomic Approaches:

  • Proximity labeling techniques (BioID, APEX) to identify MT4-MMP interaction partners

  • Mass spectrometry-based identification of MT4-MMP substrates in different tissue contexts

• Structural Biology:

  • Cryo-EM studies of MT4-MMP alone and in complex with substrates or inhibitors

  • X-ray crystallography of MT4-MMP catalytic domain with bound antibodies to map epitopes

• Functional Genomics:

  • CRISPR-Cas9 screening to identify genes that modify MT4-MMP activity

  • Domain-specific mutations to correlate structure with function

• Activity-Based Probes:

  • Development of specific activity-based probes that bind only to the active form of MT4-MMP

  • Dual-labeled probes that allow simultaneous detection of MT4-MMP expression and activity

• Antibody Engineering:

  • Development of conformation-specific antibodies that recognize only the active or inactive forms

  • Creation of antibody-enzyme conjugates for proximity-based detection of MT4-MMP activity